Matthew Lang Net Worth

The estimated Net Worth of Matthew Lang is at least $15.9 millió dollars as of 18 January 2023. Mr. Lang owns over 1,272 units of Myovant Sciences Ltd stock worth over $9,559,095 and over the last 7 years he sold MYOV stock worth over $1,872,835. In addition, he makes $4,503,000 as General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences és Inc. at Myovant Sciences Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Lang MYOV stock SEC Form 4 insiders trading

Matthew has made over 20 trades of the Myovant Sciences Ltd stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,272 units of MYOV stock worth $34,204 on 18 January 2023.

The largest trade he's ever made was selling 31,214 units of Myovant Sciences Ltd stock on 12 August 2022 worth over $569,031. On average, Matthew trades about 6,962 units every 40 days since 2017. As of 18 January 2023 he still owns at least 354,303 units of Myovant Sciences Ltd stock.

You can see the complete history of Mr. Lang stock trades at the bottom of the page.

Matthew Lang biography

Matthew Lang serves as General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc. of the Company. of the Company. of the Company. of the Company. of the Company. of the Company. Mr. Lang also currently serves as the Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc. Mr. Lang was previously Vice President, Head of Global Litigation, Investigations, Employment Law and Information Governance at Gilead Sciences, Inc., a biopharmaceutical company, where he worked from November 2009 to July 2017. At Gilead, in addition to leading core functions within the legal department, Mr. Lang was a member of the company’s Corporate Operating Group, Global Legal Leadership Team and the Global Compliance Committee. Prior to Gilead, from 2003 to 2009, Mr. Lang was an attorney at Dechert LLP in New York City, where he represented companies and executives in regulatory enforcement matters, internal investigations, criminal defense matters, labor disputes, and other civil litigation and appeals. Mr. Lang served as a member of the board of directors of the United Way Bay Area from 2015 to 2018. Mr. Lang received his B.A. in Classical Studies from Queen’s University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School.

What is the salary of Matthew Lang?

As the General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences és Inc. of Myovant Sciences Ltd, the total compensation of Matthew Lang at Myovant Sciences Ltd is $4,503,000. There are 1 executives at Myovant Sciences Ltd getting paid more, with Lynn Seely having the highest compensation of $6,222,670.

How old is Matthew Lang?

Matthew Lang is 44, he's been the General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences és Inc. of Myovant Sciences Ltd since 2019. There are 13 older and no younger executives at Myovant Sciences Ltd. The oldest executive at Myovant Sciences Ltd is Kathleen Sebelius, 72, who is the Lead Independent Director.

What's Matthew Lang's mailing address?

Matthew's mailing address filed with the SEC is C/O MYOVANT SCIENCES, INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE, CA, 94005.

Insiders trading at Myovant Sciences Ltd

Over the last 8 years, insiders at Myovant Sciences Ltd have traded over $5,780,890 worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth $2,001,605,371 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... és Andrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $25,106,967. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth $1,393,178,400.

What does Myovant Sciences Ltd do?

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.

Complete history of Mr. Lang stock trades at Myovant Sciences Ltd

Myovant Sciences Ltd executives and stock owners

Myovant Sciences Ltd executives and other stock owners filed with the SEC include:

• Lynn Seely,
  Principal Executive Officer, Director
• Matthew Lang,
  General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
• Frank Karbe,
  Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc.
• Juan Camilo Arjona Ferreira,
  Chief Commercial Officer - Myovant Sciences, Inc
• David C. Marek,
  CEO & Director
• Matthew Lang J.D.,
  Gen. Counsel & Corp. Sec.
• Kathleen Sebelius,
  Lead Independent Director
• Myrtle Potter,
  Chairman of the Board
• Mark Guinan,
  Independent Director
• Terrie Curran,
  Independent Director
• Adele Gulfo,
  Director, Interim Chief Commercial Officer
• Hiroshi Nomura,
  Director
• Dr. Andria Langenberg M.D.,
  Head of Drug Safety & Pharmacovigilance
• Dr. Teresa Perney Ph.D.,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Juan Camilo Arjona Ferreira M.D.,
  Chief Medical Officer
• Bryan Selby,
  Sr. VP of Product Devel.
• Julie Tran MBA, MSHR,
  Sr. VP of HR
• Albert Liao,
  Director of Corp. Communications
• Ryan Crowe,
  VP of Investor Relations
• Uneek Mehra,
  Chief Financial & Bus. Officer
• Kim Sablich,
  Chief Commercial Officer
• Uneek Mehra,
  Principal Financial Officer
• David C Marek,
  Principal Executive Officer
• Wayne S De Veydt,
  Director
• Mark Altmeyer,
  Director
• Pharmaceuticals Internation...,
  10% owner
• Global Investors Lp Viking ...,
  
• Holdings Ltd.Dexcel Pharma ...,
  
• Global Performance Llc Viki...,
  
• Investments (Uk) Ltd Soft B...,
  
• Sciences Ltd. Roivant,
  10% owner
• Patrick Machado,
  
• Associates Gp Llcqvt Fund V...,
  
• Global Performance Llc Viki...,
  
• Pharmaceuticals Internation...,
  
• Frank Torti,
  Director
• Chemical Co., Ltd.Sumitomo ...,
  
• Lauren Merendino,
  Chief Commercial Officer
• Nancy Valente,
  Director